Evaluation of Pre-Sarcopenia and Sarcopenia in a Well-Nourished Late-Middle-Aged Population: A Feasibility Study of a Registry

Document Type : Research Paper


1 Department of Nutrition Sciences, Varastegan Institute for Medical Sciences, Mashhad, Iran.

2 Faculty of Medicine, University of Milan, Milan, Italy.

3 Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

4 Department of Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran.

5 Department of Community Medicine and Public Health, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

6 Faculty of Medicine, Krida Wacana Christian University, Jakarta, Indonesia.

7 Division of Medical Education, Brighton, and Sussex Medical School, Falmer, Brighton, BN1 9PH, Sussex, UK.


Introduction : Sarcopenia is characterized by weakness of the skeletal muscles. This study aimed to evaluate the prevalence of sarcopenia and its relationship with dietary intake, socioeconomic status, depression, lifestyle, and physical activity for the first time in a well-nourished over 55 year’s old population. Methods: This study was conducted on a well-nourished above 55 years old population. The European Working Group on Sarcopenia in Older People-2 (EWGSOP-2) guideline was used to determine the prevalence of sarcopenia. Muscle mass was assessed using bioelectrical impedance analysis. Muscle strength and performance were evaluated using handgrip and gait speed, respectively. The dietary intake, socioeconomic status, psychological health, lifestyle, clinical factors, and physical activity were examined using valid tools. Results: A total of 766 well-nourished individuals (mean age=65.14±6.84 years old; male:female ratio= 1:1.99) were evaluated for sarcopenia. The prevalence of pre-, confirmed-, and severe sarcopenia were 23.9%, 1.8%, and 1.3%, respectively. Age was significantly related to sarcopenia (OR=1.096 (95% CI: 1.069-1.124), p<0.001). Females had an increased risk of pre-sarcopenia (OR=2.189 [95% CI: 1.48-3.239], p=0.002), while males were at higher risk of confirmed and severe sarcopenia (OR=15.102 [95% CI: 4.461-51.131], p<0.001). The decision tree model of sarcopenia indicated age as the main predictor for sarcopenia. Conclusion: According to EWGSOP-2, the overall prevalence of sarcopenia was 27% among well-nourished almost healthy elderly population. There was a relationship between age and sarcopenia. Females and males were at higher risk of pre-sarcopenia and confirmed and severe sarcopenia; respectively. Further research is strongly suggested to asses pre-sarcopenia. 


  1. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. The Lancet. 2019.
  2. Dent E, Morley J, Cruz-Jentoft A, Arai H, Kritchevsky S, Guralnik J, et al. International clinical practice guidelines for sarcopenia (ICFSR): screening, diagnosis and management. J Nutr Health Aging. 2018;22(10):1148-61.
  3. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31.
  4. Zhuang C-L, Shen X, Zou H-B, Dong Q-T, Cai H-Y, Chen X-L, et al. EWGSOP2 versus EWGSOP1 for sarcopenia to predict prognosis in patients with gastric cancer after radical gastrectomy: Analysis from a large-scale prospective study. Clin Nutr. 2019.
  5. Ethgen O, Beaudart C, Buckinx F, Bruyère O, Reginster J-Y. The future prevalence of sarcopenia in Europe: a claim for public health action. Calcif Tissue Int. 2017;100(3):229-34.
  6. Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R. Prevalence of sarcopenia in the world: a systematic review and meta-analysis of general population studies. J Diabetes Metab Disord. 2017;16(1):21.
  7. Petermann‐Rocha F, Balntzi V, Gray SR, Lara J, Ho FK, Pell JP, et al. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta‐analysis. J Cachexia Sarcopenia Muscle. 2022;13(1):86-99.
  8. Kitamura A, Seino S, Abe T, Nofuji Y, Yokoyama Y, Amano H, et al. Sarcopenia: prevalence, associated factors, and the risk of mortality and disability in Japanese older adults. J Cachexia Sarcopenia Muscle. 2021;12(1):30-8.
  9. Sanchez-Rodriguez D, Bruyère O. The International Registry of patients with sarcopenia: applying research in sarcopenia to clinical practice. Springer; 2018; 735-8.
  10. Shadmand Foumani Moghadam MR, Dahakzade F, Shariatmadar Tehrani N, Molavi SF, Kavoosi F, Hosseini Z. The High Prevalence of Malnutrition in the Cancer Patients Admitted to Omid Hospital in Mashhad, Iran Based on the PG-SGA Questionnaire (2020). J Nutr Fast Health. 2021;9(1):43-9.
  11. Rubenstein LZ, Harker JO, Salvà A, Guigoz Y, Vellas B. Screening for undernutrition in geriatric practice: developing the short-form mini-nutritional assessment (MNA-SF). The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2001;56(6):M366-M72.
  12. Gupta N, Balasekaran G, Govindaswamy VV, Hwa CY, Shun LM. Comparison of body composition with bioelectric impedance (BIA) and dual energy X-ray absorptiometry (DEXA) among Singapore Chinese. J Sci Med Sport. 2011;14(1):33-5.
  13. Gonzalez MC, Heymsfield SB. Bioelectrical impedance analysis for diagnosing sarcopenia and cachexia: what are we really estimating?. J Cachexia Sarcopenia Muscle. 2017;8(2):187-9.
  14. Di Vincenzo O, Marra M, Di Gregorio A, Pasanisi F, Scalfi L. Bioelectrical impedance analysis (BIA)-derived phase angle in sarcopenia: a systematic review. Clin Nutr. 2021;40(5):3052-61.
  15. Maughan R. An evaluation of a bioelectrical impedance analyser for the estimation of body fat content. British journal of sports medicine. 1993;27(1):63-6.
  16. Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, et al. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing. 2011;40(4):423-9.
  17. Schaap LA, Quirke T, Wijnhoven HA, Visser M. Changes in body mass index and mid-upper arm circumference in relation to all-cause mortality in older adults. Clin Nutr. 2018;37(6):2252-9.
  18. Hashimoto Y, Kaji A, Sakai R, Hamaguchi M, Okada H, Ushigome E, et al. Sarcopenia is associated with blood pressure variability in older patients with type 2 diabetes: A cross‐sectional study of the KAMOGAWA‐DM cohort study. Geriatr Gerontol Int. 2018;18(9):1345-9.
  19. Moghaddam MB, Aghdam FB, Jafarabadi MA, Allahverdipour H, Nikookheslat SD, Safarpour S. The Iranian Version of International Physical Activity Questionnaire (IPAQ) in Iran: content and construct validity, factor structure, internal consistency and stability. World Appl Sci J. 2012;18(8):1073-80.
  20. Montazeri A, Goshtasebi A, Vahdaninia M, Gandek B. The Short Form Health Survey (SF-36): translation and validation study of the Iranian version. Qual Life Res. 2005;14(3):875-82.
  21. Beaudart C, Biver E, Reginster JY, Rizzoli R, Rolland Y, Bautmans I, et al. Validation of the SarQoL®, a specific health‐related quality of life questionnaire for Sarcopenia. J Cachexia Sarcopenia Muscle. 2017;8(2):238-44.
  22. Dadfar M, Kalibatseva Z. Psychometric properties of the persian version of the short beck depression inventory with Iranian psychiatric outpatients. Scientifica. 2016;2016.
  23. Sahebi A, Asghari MJ, Salari RS. Validation of depression anxiety and stress scale (DASS-21) for an Iranian population. 2005.
  24. Sharifi SF, Javadi M, Barikani A. Reliability and validity of short food frequency questionnaire among pregnant females. Biotechnology and health sciences. 2016;3(2).
  25. Ayoubi SS, Nematy M, Amini M, Esmaily H, Movahed S, Karbin K, et al. Development, validity and reproducibility of a dish-based semi-quantitative food frequency questionnaire in Iran. Med J Nutrition Metab. 2021(Preprint):1-10.
  26. Knüppel S, Norman K, Boeing H. Is a Single 24-hour Dietary Recall per Person Sufficient to Estimate the Population Distribution of Usual Dietary Intake?. J Nutr. 2019;149(9):1491-2.
  27. Luo H, Dodd KW, Arnold CD, Engle-Stone R. A New Statistical Method for Estimating Usual Intakes of Nearly-Daily Consumed Foods and Nutrients Through Use of Only One 24-hour Dietary Recall. J Nutr. 2019;149(9):1667-73.
  28. Coll PP, Phu S, Hajjar SH, Kirk B, Duque G, Taxel P. The prevention of osteoporosis and sarcopenia in older adults. JAm Geriatr Soc. 2021;69(5):1388-98.
  29. Shafiee G, Heshmat R, Ostovar A, Khatami F, Fahimfar N, Arzaghi SM, et al. Comparison of EWGSOP-1and EWGSOP-2 diagnostic criteria on prevalence of and risk factors for sarcopenia among Iranian older people: the Bushehr Elderly Health (BEH) program.
  30. Fahimfar N, Gharibzadeh S, Khashayar P, Rajabian R, Omrani GR, Bahrami A, et al. Iranian Multicenter Osteoporosis Studies (IMOS) during last decade: rationale, main findings, lessons learned and the way forward. J Diabetes Metab Disord. 2020:1-6.
  31. Hashemi R, Shafiee G, Motlagh AD, Pasalar P, Esmailzadeh A, Siassi F, et al. Sarcopenia and its associated factors in Iranian older individuals: results of SARIR study. Arch Gerontol Geriatr. 2016;66:18-22.
  32. Sousa-Santos AR, Afonso C, Borges N, Santos A, Padrão P, Moreira P, et al. Sarcopenia, physical frailty, undernutrition and obesity cooccurrence among Portuguese community-dwelling older adults: results from Nutrition UP 65 cross-sectional study. BMJ Open. 2020;10(6):e033661.
  33. Su Y, Hirayama K, Han T-f, Izutsu M, Yuki M. Sarcopenia prevalence and risk factors among Japanese community dwelling older adults living in a snow-covered city according to EWGSOP2. J Clin Med. 2019;8(3):291.
  34. Purcell S, MacKenzie M, Barbosa-Silva T, Dionne I, Ghosh S, Olobatuyi O, et al. Sarcopenia prevalence using different definitions in older community-dwelling Canadians. J Nutr Health Aging. 2020;24(7):783-90.
  35. Pelegrini A, Mazo GZ, Pinto AdA, Benedetti TRB, Silva DAS, Petroski EL. Sarcopenia: prevalence and associated factors among elderly from a Brazilian capital. Fisioterapia em Movimento. 2018;31.
  36. Sui SX, Holloway‐Kew KL, Hyde NK, Williams LJ, Tembo MC, Leach S, et al. Definition‐specific prevalence estimates for sarcopenia in an Australian population: the Geelong Osteoporosis Study. JCSM Clinical Reports. 2020;5(4):89-98.
  37. Pang BWJ, Wee S-L, Lau LK, Jabbar KA, Seah WT, Ng DHM, et al. Prevalence and associated factors of Sarcopenia in Singaporean adults—the Yishun Study. J Am Med Dir Assoc. 2021;22(4):885. e1-10.
  38. Liu X, Hou L, Xia X, Liu Y, Zuo Z, Zhang Y, et al. Prevalence of sarcopenia in multi ethnics adults and the association with cognitive impairment: findings from West-China health and aging trend study. BMC Geriatrics. 2020;20(1):1-10.
  39. Martone AM, Marzetti E, Salini S, Zazzara MB, Santoro L, Tosato M, et al. Sarcopenia identified according to the EWGSOP2 definition in community-living people: prevalence and clinical features. J Am Med Dir Assoc. 2020;21(10):1470-4.
  40. Yoo S, Kim D-Y, Lim H. Sarcopenia in relation to nutrition and lifestyle factors among middle-aged and older Korean adults with obesity. Eur J Nutr. 2020;59(8):3451-60.
  41. Savas S, Taşkıran E, Sarac FZ, Akcicek F. A cross-sectional study on sarcopenia using EWGSOP1 and EWGSOP2 criteria with regional thresholds and different adjustments in a specific geriatric outpatient clinic. Eur Geriatr Med. 2020;11(2):239-46.
  42. Benjumea A-M, Curcio C-L, Duque G, Gomez F. Dynapenia and sarcopenia as a risk factor for disability in a falls and fractures clinic in older persons. Open Access Maced J Medical Sci. 2018;6(2):344.
  43. Bae E-J, Kim Y-H. Factors affecting sarcopenia in Korean adults by age groups. Osong Public Health and Research Perspectives. 2017;8(3):169.
  44. Menant J, Weber F, Lo J, Sturnieks D, Close J, Sachdev P, et al. Strength measures are better than muscle mass measures in predicting health-related outcomes in older people: time to abandon the term sarcopenia?. Osteoporos Int. 2017;28(1):59-70.
  45. Santoro A, Bazzocchi A, Guidarelli G, Ostan R, Giampieri E, Mercatelli D, et al. A cross-sectional analysis of body composition among healthy elderly from the European NU-AGE study: sex and country specific features. Front Physiol. 2018;9:1693.
  46. Agha-Alinejad H, Gharakhanlou R, Farzad B, Bayati M. Norms of anthropometric, body composition measures and prevalence of overweight and obesity in urban populations of Iran. J Shahrekord Univ Med Sci. 2014;15(6):18-27.
  47. Linge J, Heymsfield SB, Dahlqvist Leinhard O. On the definition of sarcopenia in the presence of aging and obesity—Initial results from UK biobank. The Journals of Gerontology: Series A. 2020;75(7):1309-16.
  48. Petermann-Rocha F, Chen M, Gray SR, Ho FK, Pell JP, Celis-Morales C. Factors associated with sarcopenia: A cross-sectional analysis using UK Biobank. Maturitas. 2020;133:60-7.
  49. Wang P-y, Li Y, Wang Q. Sarcopenia: An underlying treatment target during the COVID-19 pandemic. Nutrition (Burbank, Los Angeles County, Calif). 2021;84:111104.